Polaryx Therapeutics, Inc. Research and Development Expense
Polaryx Therapeutics, Inc. (PLYX) reported Research and Development Expense of $719.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Polaryx Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $719.00K, a 51.05% increase year-over-year.
- Polaryx Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $679.00K, a 85.60% decline year-over-year.
- Polaryx Therapeutics, Inc. research and development expense for the quarter ending 2025-06-30 was $476.00K.
- Polaryx Therapeutics, Inc. research and development expense for the quarter ending 2025-03-31 was $4.72M.
- Polaryx Therapeutics, Inc. research and development expense for fiscal 2025 was $6.27M, a 122.91% increase from fiscal 2024.
- Polaryx Therapeutics, Inc. research and development expense for fiscal 2024 was $2.81M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $719.00K 10-Q · filed 2026-08-13 | $1.40M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $679.00K 10-Q · filed 2026-05-15 | ||
| 2025-12-31 | $6.27M 10-K · filed 2026-03-24 | ||
| 2025-06-30 | $476.00K 10-Q · filed 2026-08-13 | $5.19M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $4.72M 10-Q · filed 2026-05-15 | ||
| 2024-12-31 | $2.81M 10-K · filed 2026-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |